



OPEN

The Effect of microRNAs in the Regulation of Human *CYP3A4*: a Systematic Study using a Mathematical ModelSUBJECT AREAS:
PREDICTIVE MARKERS
COMPUTATIONAL MODELS
GENETICS RESEARCH
PHARMACOGENETICSZhiyun Wei^{1*}, Songshan Jiang^{3*}, Yiting Zhang^{1,2}, Xiaofei Wang⁵, Xueling Peng³, Chunjie Meng^{1,2}, Yichen Liu², Honglian Wang^{1,2}, Luo Guo^{1,2}, Shengying Qin^{1,2}, Lin He^{1,2}, Fengmin Shao⁴, Lirong Zhang⁵ & Qinghe Xing¹Received
31 October 2013Accepted
17 February 2014Published
5 March 2014

Correspondence and requests for materials should be addressed to F.M.S. (fengminshao@medmail.com.cn); L.R.Z. (lrzhang@zzu.edu.cn) or Q.H.X. (xingqinghe@gmail.com)

* These authors contributed equally to this work.

¹Children's Hospital and Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, PR China, ²Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai 200030, PR China, ³State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou 510006, PR China, ⁴Department of Urology, People's Hospital of Henan Province, Zhengzhou 450003, PR China, ⁵Department of Pharmacology, School of Medicine, Zhengzhou University, Zhengzhou 450052, PR China.

CYP3A4 metabolizes more than 50% of the drugs on the market. The large inter-individual differences of *CYP3A4* expression may contribute to the variability of human drug responses. Post-transcriptional regulation of *CYP3A4* is poorly understood, whereas transcriptional regulation has been studied much more thoroughly. In this study, we used multiple software programs to predict miRNAs that might bind to *CYP3A4* and identified 112 potentially functional miRNAs. Then a luciferase reporter system was used to assess the effect of the overexpression of each potentially functional miRNA in HEK 293T cells. Fourteen miRNAs that significantly decreased reporter activity were measured in human liver samples (N = 27) as candidate miRNAs. To establish a more effective way to analyze *in vivo* data for miRNA candidates, the relationship between functional miRNA and target mRNA was modeled mathematically. Taking advantage of this model, we found that hsa-miR-577, hsa-miR-1, hsa-miR-532-3p and hsa-miR-627 could significantly downregulate the translation efficiency of *CYP3A4* mRNA in liver. This study used *in silico*, *in vitro* and *in vivo* methods to progressively screen functional miRNAs for *CYP3A4* and to enhance our understanding of molecular events underlying the large inter-individual differences of *CYP3A4* expression in human populations.

The cytochrome P450 superfamily (CYP) is a group of monooxygenases that catalyze the oxidation of organic substances. The substrates of CYP enzymes include metabolic intermediates, such as lipids and steroidal hormones, as well as xenobiotic substances, including drugs and other toxic chemicals. CYPs are the major enzymes involved in drug metabolism and bioactivation, and they account for approximately 75% of the total number of different metabolic reactions. Fifty-seven human genes that code for various cytochrome P450 enzymes have been identified.

Cytochrome P450 3A4 (*CYP3A4*) is a member of the CYPs. The expression level of the *CYP3A4* gene is highest in the human liver, followed by the prostate, breast, gut, colon, small intestine and brain^{1–6}. The *CYP3A4* protein is involved in the metabolism of more than 50% of the current prescription drugs^{7–9}, and it has the greatest range of substrates among all the CYPs. As a result, *CYP3A4* is the predominant isozyme of all the CYPs expressed in adult human liver.

A large inter-individual difference (approximately 50-fold or more) has been reported for *CYP3A4* levels in the general population¹⁰ and contributes significantly to the striking individual differences in the therapeutic and toxic effects of drugs. It has been suggested that approximately 90% of the inter-individual differences in hepatic *CYP3A4* activity could be accounted for by genetics¹⁰. However, the coding variants of the *CYP3A4* gene may contribute to but are not likely to be the major cause of inter-individual differences in *CYP3A4* activity because of the low allele frequencies and limited alterations in enzyme expression and catalytic function¹¹. Therefore, the variability in *CYP3A4* levels might be explained by the dynamic facets of functional genomics related to gene expression, including transcriptional and post-transcriptional processes. Recently, transcriptional regulation of *CYP3A4* has been well studied¹², but post-transcriptional regulation remains elusive, especially downregulation by micro-RNAs (miRNAs)¹³.




Figure 1 | Relative luciferase ratio of each measured miRNA normalized to the empty vector. Black: empty vector group (control). Green: candidate miRNAs with significant ($p < 0.025$) reduction of relative luciferase activity (ratio < 0.8). Table S1 shows the data for each individual miRNA.

miRNAs are a family of short, noncoding RNAs of approximately 22 nucleotides¹⁴. Binding to complementary regions of transcripts, miRNAs play important roles in the regulation of target genes, either by repressing the translation of mRNAs (frequently in animals) or triggering their degradation (mainly in plants). At present, more than 1900 miRNAs have been identified in humans^{15,16}, and miRNAs are predicted to control approximately 60% of the genes in the human genome^{17–19}. The regulatory roles of miRNAs have received a great deal of attention, especially in the cancer field, but are still hardly known in the field of pharmacology.

Only two studies have thus far shown the involvement of miRNAs in the regulation of *CYP3A4* expression. Takagi et al. reported that *CYP3A4* can be indirectly regulated by miRNA via microRNA-148a (miR-148a)-controlled regulation of the human Pregnane X Receptor (PXR)²⁰. Pan et al. showed that miR-27b may negatively regulate *CYP3A4* protein expression in human embryonic kidney 293 cells²¹. These studies provided a useful clue for the mechanism of *CYP3A4* regulation, although a single gene can usually be regulated by multiple miRNAs²², and it is very likely that other miRNAs are also involved in the regulation of *CYP3A4* expression. A complete understanding of the role of miRNAs in the regulation of *CYP3A4* expression using large-scale screening experiments will provide new insights into *CYP3A4*-specific expression patterns and inter-individual variability, which have so far been unexplained. Furthermore, most investigations of *CYP3A4* regulation are based on studies of cell lines. These cell lines do not completely mimic the regulation of gene expression observed in normal hepatocytes because the cell lines are isolated from their natural environment, and the interactions with other liver cell types and the extracellular matrix are missing. Therefore, it is necessary to know how these regulatory pathways operate in humans.

In this study, we used *in silico*, *in vitro* and *in vivo* methods to systematically investigate the effects of miRNAs on *CYP3A4* expression and found that hsa-miR-577, hsa-miR-1, hsa-miR-532-3p and hsa-miR-627 repress the translation of *CYP3A4* mRNA.

Results

Bioinformatic prediction of miRNA binding. A total of 61, 28 and 77 miRNAs were predicted to bind *CYP3A4* mRNA by TargetScan, miRbase and DIANA, respectively. In total, 65, 40 and 7 miRNAs were predicted by one, two and all three of the software programs, respectively. Among the 112 predicted miRNAs, 105 were considered potentially functional miRNAs and were examined by luciferase reporter expression in this study. The other 7 miRNAs were not included in our miRNA expression library (unpublished data). Please see Table S1 for the list of predicted miRNAs.

Functional examination *in vitro*. From a miRNA expression library, 105 potentially functional miRNA expression vectors were chosen for a large-scale experimental validation using dual luciferase assays. Expression of the psiCHECK2-*CYP3A4* 3'UTR vector characterized by the ratio of *Renilla* activity/firefly activity was compared between the empty vector group (control) and each miRNA group. Candidate miRNAs were chosen according to the following criteria: (1) the relative luciferase ratios were lower than 0.8, normalized to the empty vector; (2) the relative luciferase ratios were significantly different from that of the empty vector, with p values lower than 0.025; (3) both criteria were reproducible. Among the miRNAs assayed (Figure 1), 14 candidate miRNAs were found (Table 1) and investigated in liver samples. Please see Table S1 for the relative luciferase ratios of all predicted miRNAs.

A mathematical model for miRNA function. The mathematical model we established is explained with details in the Supplemental Results. In brief, our model showed that a functional miRNA should theoretically have the following relationship with its target:

$$\frac{1}{e_{translation}} = A + B \cdot c_s,$$

where A and B are constants, c_s is the concentration of miRNA and $e_{translation}$ the “translation efficiency”, is the ratio of protein concentration to mRNA concentration of the target.

To our knowledge, there has been no gold standard to correlate a miRNA with its potential target. The most common method is the linear correlation of miRNA concentration with either mRNA or protein concentration. A better method was proposed by Takagi et al.²⁰, in which translation efficiency was used empirically. Our model refined their method and provided a theoretical foundation. In addition, the linear correlation in our model is convenient for researchers to evaluate statistical significance. Therefore, we took advantage of this model to screen functional miRNAs from candidates *in vivo*.

Clinical investigation. Enzymatic activity, relative protein concentration, relative mRNA concentration of *CYP3A4* and relative concentration of 14 candidate miRNAs were measured in 27 liver samples. All of these data were normally distributed, as verified by the one-sample Kolmogorov-Smirnov test ($p > 0.05$). As shown in Figure 2, the enzymatic activity was significantly correlated with the relative protein concentration ($p = 5.97E-07$, $R^2 = 0.638$), and the latter was also significantly correlated with the relative mRNA concentration ($p = 2.82E-05$, $R^2 = 0.511$).

Among 14 candidate functional miRNAs, hsa-miR-577, hsa-miR-1, hsa-miR-532-3p and hsa-miR-627 showed significant linear cor-



Table 1 | Candidate miRNAs that significantly reduced luciferase reporter expression

miRNA	Relative luciferase ratio (Normalized to the empty vector)	p value
hsa-mir-27b	0.544 ± 0.143	0.018
hsa-mir-627	0.656 ± 0.070	0.016
hsa-mir-653	0.672 ± 0.012	0.006
hsa-miR-660	0.684 ± 0.058	0.006
hsa-miR-361-3p	0.718 ± 0.056	0.014
hsa-miR-613	0.719 ± 0.046	0.008
hsa-miR-526b	0.739 ± 0.041	0.020
hsa-miR-569	0.740 ± 0.077	9E-04
hsa-miR-548a-3p	0.761 ± 0.034	0.019
hsa-miR-1	0.764 ± 0.091	0.013
hsa-miR-629	0.769 ± 0.058	0.008
hsa-miR-532-3p	0.773 ± 0.049	0.010
hsa-miR-559	0.790 ± 0.062	0.006
hsa-miR-577	0.799 ± 0.030	0.006

Data are expressed as the mean ± SD.

relations ($p < 0.05$) with the reciprocal of translation efficiency (Figure 3). The concentrations of hsa-miR-569, hsa-miR-559, hsa-miR-613, hsa-miR-653 and hsa-miR-526b were too low to be analyzed. Moreover, hsa-miR-577 and hsa-miR-1 also correlated significantly with translation efficiency using Spearman's rank method.

Rescue validation. To verify the direct targeting, rather than an indirect mechanism, of the four regulatory miRNAs identified above, we designed *CYP3A4* 3'UTR vectors with mutated miRNA binding sites to test the rescuing effect of each miRNA *in vitro*. Multiple binding sites were mutated for hsa-miR-532-3p because it has three predicted targets. At each binding site, six to twelve base pairs were mutated to complementary sequences using QuikChange II XL Site-Directed Mutagenesis Kits (Agilent Technologies, Santa Clara, CA) so that the corresponding miRNAs could not target the mutant mRNAs. The success of the mutagenesis was confirmed by sequencing. Co-transfection of the mutated *CYP3A4* 3'UTR vectors with the corresponding miRNA expression vectors showed that all four functional miRNAs identified in this study interacted with the

CYP3A4 3'UTR to perform their post-transcriptional regulation (Figure 4).

Discussion

There is a huge inter-individual variability of *CYP3A4* levels in human populations. Such variability may be caused post-transcriptionally by miRNAs. In the present study, we aimed to clarify whether and which miRNAs influenced human *CYP3A4* gene expression. We began the study using a computational prediction of miRNA binding to *CYP3A4* mRNA, which revealed 112 potentially functional miRNAs. The luciferase reporter cloned with the human *CYP3A4* 3'-UTR fragment was then used to evaluate the effect of each potentially functional miRNA on gene expression in HEK 293T cells. A total of 14 miRNAs with significant repression effects was chosen as the candidates for further investigation. Using our mathematical model, four candidate miRNAs (hsa-miR-577, hsa-miR-1, hsa-miR-532-3p and hsa-miR-627) were found to significantly influence the translation efficiency of *CYP3A4* mRNA in human liver samples (Figure S1).




Figure 2 | The relationship between mRNA concentration, protein concentration and enzymatic activity of *CYP3A4* in liver samples. (A), The *CYP3A4* mRNA level was significantly correlated with the *CYP3A4* protein level. (B), The *CYP3A4* enzymatic activity was significantly correlated with the *CYP3A4* mRNA level. $N = 27$.



A

		miR-577	miR-27b	miR-660	miR-1	miR-629	miR-532-3p	miR-548a-3p	miR-627	miR-361-3p
Linear regression	p value	0.001	0.105	0.058	0.003	0.240	0.022	0.962	0.015	0.075
	q value	0.009	0.135	0.104	0.014	0.270	0.049	0.962	0.045	0.113
Spearman Rank test	p value	0.025	0.188	0.221	0.007	0.290	0.038	0.925	0.086	0.157
	q value	0.113	0.282	0.284	0.063	0.326	0.114	0.925	0.194	0.283




Figure 3 | The correlation between each miRNA and $1/e_{\text{translation}}$ (mRNA/protein) of *CYP3A4* in human liver samples. (A), The significance of linear regression and Spearman's rank test between candidate miRNAs and $1/e_{\text{translation}}$. Significant p values or q values are in **boldface**. (B), (C), (D) and (E), the $1/e_{\text{translation}}$ of *CYP3A4* was significantly correlated with the relative concentration of hsa-miR-577 (B), hsa-miR-1 (C), hsa-miR-532-3p (D) and hsa-miR-627 (E). N = 27.




Figure 4 | Rescue validation for four functional miRNAs. The *CYP3A4* 3'UTR vector was mutated to produce several rescue vectors that did not have the corresponding miRNA binding sites. After mutagenesis, the expression of the *CYP3A4* 3'UTR vectors was no longer significantly affected by hsa-miR-577 (A), hsa-miR-1 (B), hsa-miR-532-3p (C) or hsa-miR-627 (D).

Although the roles of miRNAs in the regulation of the cytochrome P450s have only begun to become clear, many studies have reported interesting findings. The first study revealing the regulation of P450 by miRNA²³ found that hsa-miR-27b downregulated human CYP1B1²⁴. In addition, hsa-miR-27b was reported to decrease human *CYP3A4* expression using the luciferase reporter²¹. This result is consistent with our *in vitro* result but not in our liver samples. Human CYP2E1 and CYP24A1 were found to be repressed by hsa-miR-378²⁵ and hsa-miR-125b²⁶, respectively. In addition, miR-126* was reported to regulate CYP2A4 in rats²⁷. All of the studies mentioned indicated that miRNAs participate in the regulation of CYPs.

All of the miRNAs we found to affect *CYP3A4* expression, especially hsa-miR-1, have been reported to be involved to some extent in various cancers. Both hsa-miR-577 and hsa-miR-1 were found to be significantly associated with chemosensitivity after chemotherapy for gastric cancer²⁸, which may be partly explained by their influence on the cytochrome P450 enzymes.

In our simplified mathematical model, there are many issues that need to be addressed cautiously. (1) Because this model aimed to evaluate whether and how much each miRNA regulated the expression of a certain gene in a population, it was assumed that the miRNA level was the unique variable. Therefore, individual differences of

transcription efficiency and of decay rates were neglected. (2) In metazoans, including humans, miRNAs function with non-perfect target matches primarily by blocking translation, whereas miRNAs in plants function with perfect or near-perfect matches and cause mRNA degradation. Our model only considered the function of miRNAs in translation repression because the subjects are human, and it is not applicable to the study of miRNAs in plants. (3) We also neglected the one-to-multiple relationships between mRNA and miRNA because a one-to-one relationship has not been well understood. (4) Feedback widely exists in biological events but is not considered in this model. All these simplifications were designed to reveal a linear correlation to assess the significance of the influence of a miRNA that would be practically useful for clinical investigations. However, such practical applicability sacrificed the accuracy of the mathematical model. For more accurate but complicated models, please see the literature^{29,30}. Better models for practical applications are urgently needed because *in vivo* miRNA studies are beginning to multiply.

The concept of “translation efficiency” was proposed by Takagi et al²⁰ to minimize the transcriptional differences of evaluating the post-transcriptional regulation by miRNAs. In our model, we found that the reciprocal of the translation efficiency was theoretically linearly correlated with miRNA level, which is the reason we used linear



regression in the data analysis. In addition, we also performed Spearman's rank test to correlate ranks of translation efficiency and those of miRNAs in the population, as used in Takagi's study²⁰, which revealed less significant but similar findings.

Although using a single reference gene is still a common practice, it may introduce a bias into qPCR results. To minimize such a possibility, we also measured other widely used reference genes in the liver samples. As shown in Figure S2, there were significant correlations of expression between two reference mRNAs (GAPDH and ACTB) and between two reference small RNAs (U6 and SNORD38B) in liver samples, which suggested that only a limited bias was caused by the arbitrary reference genes in this study. Future studies with more reference genes and better normalization, e.g., geNorm³¹, in bigger sample size are warranted to confirm the functional miRNAs we identified in the current study.

To minimize the possibility of losing any functional miRNAs for subsequent *in vivo* investigations, we did not use any correction in our luciferase reporter experiments *in vitro*. This strategy is reasonable because any false-positive results from *in vitro* examination can be verified by *in vivo* investigations. Moreover, triplicates in each group are not suitable for correction in high-throughput *in vitro* examination. Arbitrarily, we set the p value threshold to 0.025 to limit the number of candidate miRNAs.

In clinical investigations, the FDR (false discovery rate) correction was used to avoid false-positive conclusions caused by multiple comparisons. As shown in Figure 3A, all of the hsa-miR-577, hsa-miR-1, hsa-miR-532-3p and hsa-miR-627 results were still significant after the FDR correction ($q < 0.05$) of the linear regression analysis. However, significance for miRNAs decreased after the FDR correction in Spearman's rank test, which suggested that our mathematical model may analyze miRNA function better than traditional methods.

This study systematically investigated miRNAs *in silico*, *in vitro* and *in vivo*, considering all known miRNAs as targets and examining them in a high-throughput system. Moreover, the use of liver samples consolidated our conclusions because miRNAs exhibit unique expression patterns in specific cells and/or tissues at various developmental stages, and the liver is the principal site where CYP3A4 metabolizes drugs. These miRNAs involved in the regulation of human liver CYP3A4 expression are potential biomarkers that can be used to guide personalized medicine. In addition, our simplified mathematical model provides a theoretical basis for the empirical use of translational efficiency in analyses of miRNA functions.

However, the sample size of liver samples is still small, although similar to those of other studies. This increases the risk of type II errors (false-negative errors), as observed by the power = 0.61 with a medium size effect ($f^2 = 0.2$). In addition, we could not rule out the possibility of indirect regulation of miRNAs by other proteins, which becomes a serious issue for miRNA studies. Finally, future studies with appropriate animal models may assist in confirming the regulation of CYP3A4 expression by miRNAs.

In this systematic study, we first found 112 miRNAs that potentially regulate CYP3A4 from miRNA databases *in silico*. Then, we used an overexpression method with a luciferase reporter system to identify 14 candidate miRNAs *in vitro*. Finally, four miRNAs were found to correlate significantly with the reciprocal of the translation efficiency of CYP3A4 in human liver samples *in vivo*, following our mathematical model. We concluded that human CYP3A4 is post-transcriptionally regulated by hsa-miR-577, hsa-miR-1, hsa-miR-532-3p and hsa-miR-627 in liver. This study enhanced our understanding of the molecular events underlying the large inter-individual differences of CYP3A4 expression in human populations, which would be a potent risk factor for drug response variability.

Methods

Ethics statement. The protocol complied with the Declaration of Helsinki and its subsequent revisions and was approved by the Ethics Committees of Zhengzhou University.

Bioinformatics prediction. The miRNA binding was predicted using three online software programs: TargetScan (v6.2; <http://www.targetscan.org/>)³², miRanda in combination with mirSVR (August 2010 release; <http://www.microrna.org/microrna/getGeneForm.do>)³³ and DIANA (v3.0; <http://diana.cslab.ece.ntua.gr/microT/>)³⁴ with default thresholds. The full-length sequence of the human CYP3A4 3'-UTR was input into the prediction, if available.

Luciferase reporter activity assay. Human CYP3A4 3'-UTR fragments, corresponding to nucleotides +26057 to +27229 in the CYP3A4 gene (NG_008421), were PCR-amplified from genomic DNA and cloned into the psiCHECK2 vector (Promega, Madison, WI) downstream of the *Renilla* luciferase reporter gene. The psiCHECK2 vector also includes an independent firefly luciferase reporter gene, which functions as a control for transfection efficiency. This psiCHECK2-CYP3A4 vector was transiently co-transfected with each miRNA expression vector or empty pLL3.7 vector (control) into HEK 293T cells, using Lipofectamine 2000 (Life Technologies, Carlsbad, CA). The miRNA expression library was constructed based on the miRBase reference database (August 2010 Release). The *Renilla* and firefly luciferase activities in cell lysates were measured 48 hours after transfection using the dual-luciferase reporter assay system (Promega), and the results were expressed as the ratio of *Renilla* activity/firefly activity in the lysate. Each experiment included at least three replicates. The difference between the miRNA group and the control was evaluated using a *t*-test.

Tissue samples. Human liver samples from 27 Chinese Han donors were obtained from the First Affiliated Hospital of Zhengzhou University after informed consent. Liver samples were stored in liquid nitrogen immediately after resection. Total RNAs were extracted from approximately 0.1 g of liver using the standard TRIzol method (Life Technologies) followed by agarose gel electrophoresis for quality control. Randomly selected RNA samples were also examined using an Agilent Bioanalyzer (Agilent Technologies) for further quality control (RIN value > 7). RNA concentration was measured using a NanoDrop 2000c (Thermo Fisher Scientific, Waltham, MA). Total proteins were extracted from approximately 0.3 g of liver using RIPA lysis buffer containing the protease inhibitor PMSF followed by quantification using the BCA method (Pierce, Rockford, Illinois).

Immunoblot analysis. Total protein (20 μ g) was input in 10% SDS-PAGE gels and transferred electrophoretically to nitrocellulose membranes. The membranes were blocked with 5% (wt/vol) powdered/dry milk in Tris-buffered saline with 0.1% Tween-20. After incubation with a primary rabbit anti-CYP3A4 antibody (ab3572; Abcam, MA), the membranes were washed and incubated with a secondary antibody. The membranes were then developed using the Supersignal west pico-chemiluminescent substrate (Pierce). Anti-GAPDH was used as the endogenous control. Quantification of immunoreactive bands was performed using Quantity One system (Bio-Rad, Hercules, California).

CYP3A4 enzymatic activity. Liver microsomes were extracted from tissue using the CaCl_2 method. The BCA method was used to measure total protein concentration (Pierce). Midazolam (0.25–75 μ mol/L) was incubated with liver microsomes at 37°C for 10 minutes. The 1'-OH midazolam concentration was measured using an Agilent 1200 HPLC (Agilent Technologies). Michaelis constants (K_m , μ M) were estimated to quantify enzymatic activity with five replicates.

qPCR for mRNA and miRNA. Total RNA (500 ng) was reverse transcribed to cDNA using PrimeScript RT Reagent kits (Takara Bio, Dalian, China). The relative expression of CYP3A4 mRNA was measured by qPCR using the appropriate primers (forward, 5'-CCAAGCTATGCTCTTCCACCG-3'; reverse, 5'-TCAGGCTCCACTTACGGTGC-3') and the FastStart Universal SYBR Green Master (Roche, Germany) according to the manufacturer's protocol. GAPDH mRNA was quantified as the endogenous control using the appropriate primers (forward, 5'-ATCACCATCTTCCAGGAGCGA-3'; reverse, 5'-GCTTACCACCTTCTTG-ATGT-3'). For both sets of qPCR primers, the forward primer and the reverse primer were designed to target different exons to avoid the possibility of amplifying genomic DNA. The specificity of the qPCR primers was verified by the presence of a single peak in the melting curves. For miRNA quantification, reverse transcription and qPCR were performed using the miRCURY LNA™ Universal RT microRNA PCR system (Exiqon, Denmark) following the manufacturer's protocol. The U6 snRNA was measured as the endogenous control. All qPCRs were run on a ViiA 7 instrument (Life Technologies) with three replicates. The C_q values were determined automatically by the ViiA 7 RUO Software v1.1 (Life Technologies). All NTCS' C_q values were higher than 40 and were labeled as "undetermined" by the ViiA 7 RUO Software v1.1.

Statistics. Linear regressions and Spearman's rank correlations were determined using SPSS (Statistical Package for the Social Sciences) for Windows, version 11.0 (IBM, NY). All tests were two-tailed, and statistical significance was assumed at $p < 0.05$.

- Guengerich, F. P. Cytochrome P-450 3A4: regulation and role in drug metabolism. *Annu Rev Pharmacol Toxicol* **39**, 1–17, doi:10.1146/annurev.pharmtox.39.1.1 (1999).



2. Watkins, P. B., Wrighton, S. A., Schuetz, E. G., Molowa, D. T. & Guzelian, P. S. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. *J Clin Invest* **80**, 1029–1036, doi:10.1172/JCI113156 (1987).
3. Lown, K. S. *et al.* Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. *J Clin Invest* **99**, 2545–2553, doi:10.1172/JCI119439 (1997).
4. Kolars, J. C. *et al.* CYP3A gene expression in human gut epithelium. *Pharmacogenetics* **4**, 247–259 (1994).
5. Huang, Z., Fasco, M. J., Figge, H. L., Keyomarsi, K. & Kaminsky, L. S. Expression of cytochromes P450 in human breast tissue and tumors. *Drug Metab Dispos* **24**, 899–905 (1996).
6. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. & Guengerich, F. P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. *J Pharmacol Exp Ther* **270**, 414–423 (1994).
7. Blumberg, B. *et al.* SXR, a novel steroid and xenobiotic-sensing nuclear receptor. *Genes Dev* **12**, 3195–3205 (1998).
8. Goodwin, B., Hodgson, E. & Liddle, C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. *Mol Pharmacol* **56**, 1329–1339 (1999).
9. Lehmann, J. M. *et al.* The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. *J Clin Invest* **102**, 1016–1023, doi:10.1172/JCI3703 (1998).
10. Ozdemir, V. *et al.* Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. *Pharmacogenetics* **10**, 373–388 (2000).
11. Lamba, J. K., Lin, Y. S., Schuetz, E. G. & Thummel, K. E. Genetic contribution to variable human CYP3A-mediated metabolism. *Adv Drug Deliv Rev* **54**, 1271–1294 (2002).
12. Martinez-Jimenez, C. P., Jover, R., Donato, M. T., Castell, J. V. & Gomez-Lechon, M. J. Transcriptional regulation and expression of CYP3A4 in hepatocytes. *Curr Drug Metab* **8**, 185–194 (2007).
13. Koturbash, I., Beland, F. A. & Pogribny, I. P. Role of microRNAs in the regulation of drug metabolizing and transporting genes and the response to environmental toxicants. *Expert Opin Drug Metab Toxicol* **8**, 597–606, doi:10.1517/17425255.2012.673587 (2012).
14. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* **116**, 281–297 (2004).
15. Bentwich, I. *et al.* Identification of hundreds of conserved and nonconserved human microRNAs. *Nat Genet* **37**, 766–770, doi:10.1038/ng1590 (2005).
16. Kozomara, A. & Griffiths-Jones, S. miRBase: integrating microRNA annotation and deep-sequencing data. *Nucleic Acids Res* **39**, D152–157, doi:10.1093/nar/gkq1027 (2011).
17. Lewis, B. P., Burge, C. B. & Bartel, D. P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell* **120**, 15–20, doi:10.1016/j.cell.2004.12.035 (2005).
18. Xie, X. *et al.* Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals. *Nature* **434**, 338–345, doi:10.1038/nature03441 (2005).
19. Friedman, R. C., Farh, K. K., Burge, C. B. & Bartel, D. P. Most mammalian mRNAs are conserved targets of microRNAs. *Genome Res* **19**, 92–105, doi:10.1101/gr.082701.108 (2009).
20. Takagi, S., Nakajima, M., Mohri, T. & Yokoi, T. Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. *J Biol Chem* **283**, 9674–9680, doi:10.1074/jbc.M709382200 (2008).
21. Pan, Y. Z., Gao, W. & Yu, A. M. MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. *Drug Metab Dispos* **37**, 2112–2117, doi:10.1124/dmd.109.027680 (2009).
22. Wu, S. *et al.* Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3' untranslated region. *Oncogene* **29**, 2302–2308, doi:10.1038/nc.2010.34 (2010).
23. Nakajima, M. & Yokoi, T. MicroRNAs from biology to future pharmacotherapy: regulation of cytochrome P450s and nuclear receptors. *Pharmacol Ther* **131**, 330–337, doi:10.1016/j.pharmthera.2011.04.009 (2011).
24. Tsuchiya, Y., Nakajima, M., Takagi, S., Taniya, T. & Yokoi, T. MicroRNA regulates the expression of human cytochrome P450 1B1. *Cancer Res* **66**, 9090–9098, doi:10.1158/0008-5472.CAN-06-1403 (2006).
25. Mohri, T. *et al.* Human CYP2E1 is regulated by miR-378. *Biochem Pharmacol* **79**, 1045–1052, doi:10.1016/j.bcp.2009.11.015 (2010).
26. Komagata, S. *et al.* Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b. *Mol Pharmacol* **76**, 702–709, doi:10.1124/mol.109.056986 (2009).
27. Kalscheuer, S., Zhang, X., Zeng, Y. & Upadhyaya, P. Differential expression of microRNAs in early-stage neoplastic transformation in the lungs of F344 rats chronically treated with the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. *Carcinogenesis* **29**, 2394–2399, doi:10.1093/carcin/bgn209 (2008).
28. Kim, C. H. *et al.* miRNA signature associated with outcome of gastric cancer patients following chemotherapy. *BMC Med Genomics* **4**, 79, doi:10.1186/1755-8794-4-79 (2011).
29. Levine, E., Ben Jacob, E. & Levine, H. Target-specific and global effectors in gene regulation by MicroRNA. *Biophys J* **93**, L52–54, doi:10.1529/biophysj.107.118448 (2007).
30. Zinovyev, A. *et al.* Dynamical modeling of microRNA action on the protein translation process. *BMC Syst Biol* **4**, 13, doi:10.1186/1752-0509-4-13 (2010).
31. Vandesompele, J. *et al.* Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. *Genome Biol* **3**, RESEARCH0034 (2002).
32. Grimson, A. *et al.* MicroRNA targeting specificity in mammals: determinants beyond seed pairing. *Mol Cell* **27**, 91–105, doi:10.1016/j.molcel.2007.06.017 (2007).
33. John, B. *et al.* Human MicroRNA targets. *PLoS Biol* **2**, e363, doi:10.1371/journal.pbio.0020363 (2004).
34. Maragkakis, M. *et al.* DIANA-microT web server: elucidating microRNA functions through target prediction. *Nucleic Acids Res* **37**, W273–276, doi:10.1093/nar/gkp292 (2009).

Acknowledgments

This work was supported by the National Natural Science Foundation of China [grants 30971582, 61240031 and 81173127] and the 973 Program [2010CB529600]. Those funding the study had no role in the study design, data collection and analysis, the decision to publish, or preparation of the manuscript. We are deeply grateful to all the participants as well as to the clinicians working on this project.

Author contributions

Z.W., Y.Z., C.M., Y.L. and S.Q. performed the RNA experiments. S.J. and X.P. performed the prediction and performed the experiments with the cell line. X.W., F.S. and L.Z. provided the tissue samples and performed the enzyme experiments. Y.Z. and H.W. performed the immunoblot experiments. Z.W. and L.G. performed the mathematical modeling. L.H., L.Z. and Q.X. supervised the studies. Z.W. and Q.X. designed the study and wrote the paper.

Additional information

Supplementary information accompanies this paper at <http://www.nature.com/scientificreports>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Wei, Z.Y. *et al.* The Effect of microRNAs in the Regulation of Human CYP3A4: a Systematic Study using a Mathematical Model. *Sci. Rep.* **4**, 4283; DOI:10.1038/srep04283 (2014).



This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported license. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/3.0>